Cure8 news brief
An FDA approval of an autoinjector for ustekinumab may make self‑injection easier and more convenient for people with Crohn’s disease or ulcerative colitis who use this biologic. Changes in delivery format can also affect access, insurance coverage, and patient preference.
Adults with Crohn’s disease or ulcerative colitis who use or are considering ustekinumab; caregivers who assist with injections; clinicians and pharmacists managing biologic therapies; patients tracking access/cost of biosimilars.
Biocon’s U.S. subsidiary received supplemental FDA approval for Yesintek® (ustekinumab-kfce) in a single‑dose prefilled autoinjector in two strengths (45 mg/0.5 mL and 90 mg/mL). The approval covers indications including moderate to severely active Crohn’s disease and ulcerative colitis, as well as psoriasis and psoriatic arthritis.
This is an approval of a delivery device/format (autoinjector) for an already‑approved product rather than a new molecule. For people using or considering ustekinumab, an autoinjector can offer greater convenience for at‑home administration and may influence prescribing or access depending on formulary and cost.
If you currently use ustekinumab or are discussing biologic options with your clinician, ask whether the autoinjector formulation will be available to you and whether it affects dosing, training, insurance coverage, or prior‑authorization requirements.
This update is based on the company announcement reporting FDA supplemental approval; it is not a clinical study report or label change summary from the FDA itself.
This announcement is a company update reporting a supplemental FDA approval for a delivery device (autoinjector) for Yesintek® (ustekinumab‑kfce). It does not provide detailed FDA labeling text, pricing, or rollout timelines—those details may come from the FDA label, the manufacturer, or payers.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new FDA‑approved biosimilar to ustekinumab is now available in the U.S., which may increase treatment options and lower out‑of‑pocket costs for people with Crohn’s disease or ulcerative colitis. The article highlights...
An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and...
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
